Takeda Announces Completion of New Manufacturing Facilities at the Oranienburg Site in Germany

Zurich, Switzerland and Osaka, Japan, June 16, 2017 — Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) today announced that it has completed the construction of new manufacturing facilities at its site in Oranienburg, aiming to deliver Takeda's high-quality medicines to more patients in a timely manner as well as further address patients' needs. The new facility was built at a total cost of around 100 million euros (around 12 billion yen), and is scheduled to begin operating at the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.

The importance of this investment was evidenced by the participation in the inauguration ceremonies of the Federal Chancellor of Germany, Angela Merkel, Japan's Ambassador to Germany, Takeshi Yagi, the Federal State Prime Minister of Brandenburg, Dietmar Woidke and Takeda’s President and CEO, Christophe Weber.

In a press release issued November 27, 2014, Takeda announced that, as a part of its initiative toward optimization of its global network, the manufacture of solid dosage form pharmaceutical products would be transferred from the Osaka Plant to the Oranienburg Plant and the Hikari Plant. The completion of this new manufacturing facility in Germany is an integral part of this effort.

Specialized in producing solid forms (pills and capsules), the Oranienburg site, which has a 130-year history of pharmaceutical production in Germany, plays a key role in Takeda’s global manufacturing network. Many of Takeda’s drug products are manufactured and supplied to 100 countries worldwide from the Oranienburg site, including drugs to treat diseases in gastroenterology (e.g. Pantoprazole), central nervous (e.g. Trintellix) and cardiovascular systems (e.g. Magnyl).

The expanded production capacity of the Oranienburg site will make it possible to meet the increased demand for Takeda’s products in global markets, including rapidly growing emerging markets, and has already created about 180 new jobs.
“We continuously invest in our facilities to advance our technologies in order to ensure a stable supply of high-quality drug products to patients around the world,” said Thomas Wozniewski, Global Manufacturing & Supply Officer of Takeda.

Fast Facts about New Production Facility

 

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, R&D-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its research efforts on oncology, gastroenterology and central nervous system therapeutic areas. It also has specific development programs in specialty cardiovascular diseases as well as late-stage candidates for vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. New innovative products, especially in oncology, central nervous system and gastroenterology, as well as its presence in emerging markets, fuel the growth of Takeda. Around 30,000 Takeda employees are committed to improving quality of life for patients, working with our partners in health care in more than 70 countries.

For more information, http://www.takeda.com/news

---

Media Contacts:
Media outside Japan
Jürgen Schneider
Jü[email protected]
+41 (0) 44-555-1338

 Japanese Media
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095

###